Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment

Many cancers have evolved various mechanisms to evade immunological surveillance, such as the inhibitory immune checkpoint of the CD47-SIRPα signaling pathway. By targeting this signaling pathway, researchers have developed diverse nanovehicles with different loaded drugs and modifications in antica...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Haiqin, Niu, Chengcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087583/
https://www.ncbi.nlm.nih.gov/pubmed/35557862
http://dx.doi.org/10.3389/fbioe.2022.887463
_version_ 1784704212893958144
author Liao, Haiqin
Niu, Chengcheng
author_facet Liao, Haiqin
Niu, Chengcheng
author_sort Liao, Haiqin
collection PubMed
description Many cancers have evolved various mechanisms to evade immunological surveillance, such as the inhibitory immune checkpoint of the CD47-SIRPα signaling pathway. By targeting this signaling pathway, researchers have developed diverse nanovehicles with different loaded drugs and modifications in anticancer treatment. In this review, we present a brief overview of CD47-SIRPα interaction and nanomedicine. Then, we delve into recent applications of the CD47-SIRPα interaction as a target for nanomedicine-based antitumor treatment and its combination with other targeting pathway drugs and/or therapeutic approaches.
format Online
Article
Text
id pubmed-9087583
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90875832022-05-11 Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment Liao, Haiqin Niu, Chengcheng Front Bioeng Biotechnol Bioengineering and Biotechnology Many cancers have evolved various mechanisms to evade immunological surveillance, such as the inhibitory immune checkpoint of the CD47-SIRPα signaling pathway. By targeting this signaling pathway, researchers have developed diverse nanovehicles with different loaded drugs and modifications in anticancer treatment. In this review, we present a brief overview of CD47-SIRPα interaction and nanomedicine. Then, we delve into recent applications of the CD47-SIRPα interaction as a target for nanomedicine-based antitumor treatment and its combination with other targeting pathway drugs and/or therapeutic approaches. Frontiers Media S.A. 2022-04-26 /pmc/articles/PMC9087583/ /pubmed/35557862 http://dx.doi.org/10.3389/fbioe.2022.887463 Text en Copyright © 2022 Liao and Niu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Liao, Haiqin
Niu, Chengcheng
Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
title Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
title_full Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
title_fullStr Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
title_full_unstemmed Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
title_short Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
title_sort role of cd47-sirpα checkpoint in nanomedicine-based anti-cancer treatment
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087583/
https://www.ncbi.nlm.nih.gov/pubmed/35557862
http://dx.doi.org/10.3389/fbioe.2022.887463
work_keys_str_mv AT liaohaiqin roleofcd47sirpacheckpointinnanomedicinebasedanticancertreatment
AT niuchengcheng roleofcd47sirpacheckpointinnanomedicinebasedanticancertreatment

Ejemplares similares